Trials

A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma

Cancer type: Melanoma

Phase: II

Principal Investigator: Hernberg Micaela

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03470922